Analyst Reco. ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 21:00:02 10/04/2026 BST			5-day change	1st Jan Change
228.87 ^USD	+0.39%		+2.13%	-4.98%

04-09	Resmed Insider Sold Shares Worth $1,125,486, According to a Recent SEC Filing	MT
04-08	Citigroup Adjusts Price Target on ResMed to $340 From $345, Maintains Buy Rating	MT

Analyst Reco.

04-08	Citigroup Adjusts Price Target on ResMed to $340 From $345, Maintains Buy Rating	MT
03-11	Baird Adjusts Price Target on ResMed to $272 From $281, Maintains Neutral Rating	MT
02-02	Morgans Financial Upgrades ResMed to Buy from Accumulate, Price Target is AU$47.73	MT
02-02	Analyst recommendations: Apple, Autodesk, Best Buy, Caterpillar, PayPal…
01-30	RBC Raises Price Target on ResMed to $314 From $311, Keeps Outperform Rating	MT
01-30	Wolfe Adjusts Price Target on ResMed to $230 From $225, Maintains Underperform Rating	MT
01-30	Wells Fargo Adjusts Price Target on ResMed to $270 From $265, Maintains Equalweight Rating	MT
01-30	KeyBanc Adjusts Price Target on ResMed to $302 From $299, Maintains Overweight Rating	MT
01-30	Stifel Adjusts Price Target on ResMed to $265 From $260, Maintains Hold Rating	MT
01-30	Jefferies Adjusts Price Target on ResMed to $290 From $285, Maintains Hold Rating	MT
01-30	Citigroup Adjusts Price Target on ResMed to $345 From $330, Maintains Buy Rating	MT
01-30	Baird Adjusts Price Target on ResMed to $281 From $275, Maintains Neutral Rating	MT
01-30	Piper Sandler Adjusts Price Target on ResMed to $275 From $270, Maintains Neutral Rating	MT
01-26	Morgan Stanley Adjusts ResMed Price Target to $310 From $305	MT
12-18	Stifel Nicolaus Adjusts ResMed Price Target to $260 From $270, Maintains Hold Rating	MT
12-16	Baird Downgrades ResMed to Neutral From Outperform, Adjusts Price Target to $275 From $300	MT
12-16	Analyst recommendations: Accenture, Albemarle, Eli Lilly, Gitlab, Okta…
31/10/25	Baird Adjusts Price Target on ResMed to $300 From $320	MT
31/10/25	Jefferies & Co Adjusts ResMed Price Target to $285 From $290	MT
31/10/25	Wells Fargo Adjusts ResMed Price Target to $265 From $280	MT
31/10/25	Wolfe Research Adjusts ResMed Price Target to $225 From $215	MT
31/10/25	Morgan Stanley Adjusts ResMed Price Target to $305 From $304	MT
31/10/25	Mizuho Adjusts Price Target on ResMed to $300 From $310	MT
31/10/25	KeyBanc Adjusts Price Target on ResMed to $299 From $298	MT
31/10/25	RBC Lifts Price Target on ResMed to $303 From $300, Keeps Outperform Rating	MT